PAXLOVID™ (PF-07321332; ritonavir) is now authorised in Ireland

A Conditional Marketing Authorisation (CMA) has been granted in the EU for PAXLOVID™ for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Read the PAXLOVID™ Package Leaflet: Information for the Patient

Authentic PAXLOVID™ from Pfizer will include the Pfizer name on the carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. PF-07321332 are oval, pink, film-coated tablet with “PFE” debossed on one tablet face and “3CL” debossed on the opposite tablet face. Ritonavir white tablets have R9 debossed on the front and H debossed on the back.

The flaps at each end of the carton are glued as a tamper evident feature of the packaging.

The outer carton of the box has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.

If you suspect the PAXLOVID™ you have received may be counterfeit, please report this to your local representative on 1800 633 363

Copyright © 2022 Pfizer Inc. All rights reserved. PP-PAX-IRL-0004; Date of Preparation March 2022